A mulberry leaf extract marketed as Reducose by Phynova led to significant improvements in postprandial glucose and insulin responses in a human clinical study involving 37 participants.
 
In a crossover fashion, individuals were randomized to receive either a placebo or 200 mg, 225 mg, or 250 mg and eat a meal rich in refined carbohydrates and fats. Compared to placebo, all three doses of Reducose helped to reduce blood glucose responses by 30-33% compared to placebo during the two-hour postprandial period.
 
All three doses significantly reduced peak blood glucose responses by 26-32% compared to placebo during the two-hour postprandial period, with the mean peak glucose response across all three dose groups being 6 mmol/L or less.
 
All three Reducose levels also significantly diminished total insulin release by 31-38% versus placebo.
 
Finally, the same three Reducose levels also significantly lowered peak insulin release by 27-40% versus placebo during the postprandial window, compared to levels at baseline.
 
These findings were in line with previous clinical findings on Reducose’s role in blood glucose and insulin responses, this time in response to a complete meal with macronutrient composition that was representative of the average Western diet. Previous studies investigated the effects of Reducose following consumption of maltodextrin or sucrose alone or in combination with other ingredients.
 
According to Phynova, Reducose can help support a healthy metabolic state by moderating exaggerated glycemic and insulinemic responses after consuming modern carb- and fat-rich diets, at even lower doses than previously reported. The study wasn’t powered to detect differences among Reducose levels.